Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.
- DOI
- 10.1136/jitc-2026-015029
- Published
- 2026 Jul 20
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2026-015029,
title = {Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.},
author = {Miller DM and Merkin RD and Kaufman HL and Gupta SG and Wolkow N and Adelaja A and Sullivan RJ and Patel C and Sorrentino A and Cohen S and Cimoch C and Emerick KS},
year = {2026},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2026-015029},
url = {https://doi.org/10.1136/jitc-2026-015029}
}RIS
TY - JOUR TI - Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation. AU - Miller DM AU - Merkin RD AU - Kaufman HL AU - Gupta SG AU - Wolkow N AU - Adelaja A AU - Sullivan RJ AU - Patel C AU - Sorrentino A AU - Cohen S AU - Cimoch C AU - Emerick KS PY - 2026 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2026-015029 UR - https://doi.org/10.1136/jitc-2026-015029 ER -
APA
DM, M., RD, M., HL, K., SG, G., N, W., A, A., RJ, S., C, P., A, S., S, C., C, C., & KS, E. (2026). Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-015029
Source records
- pubmed · retrieved 2026-11-10T11:24:47.219Z
- europe-pmc · retrieved 2026-11-10T11:24:47.192Z